Bookmark
Forward
Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond.
Clinical cancer research : an official journal of the American Association for Cancer Research 2023 Sep 15Sizes of these terms reflect their relevance to your search.
KRAS-mutated non-small cell lung cancer (NSCLC) is the most common genetically altered subtype of NSCLC, yet targeted therapies remain limited. Multiple studies have investigated combinations of MEK inhibitors with chemotherapy without success. Here we discuss these studies and novel approaches to targeting KRAS-mutated NSCLC. See related article by Gadgeel et al., p. 3641. ©2023 American Association for Cancer Research.
Citation
David J Cantor, Charu Aggarwal. Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Sep 15;29(18):3563-3565
Mesh Tags
Substances
PMID: 37466928
View Full Text
